Appendix 4D

Half Year Report to the Australian Stock Exchange

Name of Entity	BioTech Capital Limited
ABN	45 091 979 172
Half Year Ended	31 December 2013
Previous Corresponding Reporting Period	31 December 2012

Results for Announcement to the Market

	$'000	**Percentage increase /(decrease) over previous corresponding period**
Revenue from ordinary activities	9	(69.7)%
Profit / (loss) from ordinary activities after tax attributable to members	(1,821)	(316.6)%
Net profit / (loss) for the period attributable to members	(1,821)	(316.6)%

Dividends (distributions)	**Amount per security**	**Franked amount per security**
Dividend 31/12/13	Nil	Nil
Interim Dividend	Nil	Nil

Record date for determining entitlements to the dividends (if any)	N/A

Brief explanation of any of the figures reported above necessary to enable the figures to be understood:

Loss for the half year ended 31 December 2013 includes an impairment loss of $1,737,966 (2012: $379,053).

Dividends

Date the dividend is payable	N/A
Record date to determine entitlement to the dividend	N/A
Amount per security	N/A
Total dividend	N/A
Amount per security of foreign sourced dividend or distribution	N/A
Details of any dividend reinvestment plans in operation	N/A
The last date for receipt of an election notice for participation in any dividend reinvestment plans	N/A

NTA Backing

	Current Period	Previous corresponding period
Net tangible asset backing per ordinary security	1.8 cents	4.3 cents

Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	None
Date control gained	N/A
Consolidated profit / (loss) from ordinary activities since the date in the current period on which control was acquired	N/A
Profit / (loss) from ordinary activities of the controlled entity (or group of entities) for the whole of the previous corresponding period	N/A

Loss of Control Gained Over Entities Having Material Effect

Name of entity (or group of entities)	None
Date control lost	N/A
Consolidated profit / (loss) from ordinary activities for the current period to the date of loss of control	N/A
Profit / (loss) from ordinary activities of the controlled entity (or group of entities) while controlled for the whole of the previous corresponding period	N/A

Details of Associates and Joint Venture Entities

Name of Entity	Percentage Held		Share of Net Profit	
	Current Period	Previous Period	Current Period	Previous Period
None	N/A	N/A	N/A	N/A
Aggregate Share of Net Profits	N/A	N/A	N/A	N/A

Foreign Entities Accounting Framework

For foreign entities provide details of which accounting standards have been adopted (e.g. International Accounting Standards)

N/A

Audit/Review Status

This report is based on accounts to which one of the following applies:
(Tick one)

The accounts have been audited		The accounts have been subject to review	✓

If the accounts are subject to audit dispute or qualification, a description of the dispute or qualification:

The auditors have issued a qualified review conclusion on the half-year financial report in relation to the unlisted investment held at directors' valuation. The auditors have been unable to satisfy themselves as to the fair value of the unlisted available for sale financial assets.

Attachments Forming Part of Appendix 4D

Attachment #	Details
1	Interim Financial Report

Signed By Company Secretary	Baden Bowen
Print Name	Baden M Bowen
Date: 20 February 2014	

Attachment 1

BIOTECH CAPITAL LIMITED

ABN 45 091 979 172

HALF-YEAR FINANCIAL REPORT

FOR THE HALF YEAR ENDED

31 DECEMBER 2013

CONTENTS

BIOTECH CAPITAL LIMITED ABN 45 091 979 172

CORPORATE DIRECTORY

Principal and registered office in Australia	BioTech Capital Limited 1 Edmondson Crescent KARRINYUP WA 6018 T +61 8 9446 5293 F +61 8 6210 1567
Directors	Alastair John Davidson Harry Karelis Edward Taylor
Company Secretary	Baden Maxwell Bowen
Bankers	Westpac Banking Corporation
Share Register	Advanced Share Registry 150 Stirling Highway NEDLANDS WA 6009 PO Box 1156 NEDLANDS WA 6909 T (08) 9389 8033 F (08) 9389 7871
Auditor	Deloitte Touche Tohmatsu Level 14, Woodside Plaza 240 St Georges Terrace PERTH WA 6000
Solicitors	Dibbs Barker Level 8, Angel Place 123 Pitt Street SYDNEY NSW 2000
Internet Address	www.biotechcapital.com.au

BIOTECH CAPITAL LIMITED ABN 45 091 979 172

HALF-YEAR FINANCIAL REPORT

DIRECTORS' REPORT

Your directors submit the financial report of the company for the half-year ended 31 December 2013.

Directors

Alastair John Davidson
Harry Karelis
Edward Taylor

Review of Operations

The following is a review of operations for the six-month period to 31 December 2013:

The loss of $1,820,936 (2012: $437,136) included an impairment loss on unlisted investments of $1,737,966 (2012: $379,053). The Company maintained its one remaining investment in Sensear Pty Ltd.

Auditor's Declaration of Independence

A copy of the auditor's declaration under section 307C in relation to the half year is attached.

This report is signed in accordance with a resolution of the Board of Directors made pursuant to s.306(3) of the Corporations Act 2001.

E Taylor
Director

Dated this 20th day of February 2014

Deloitte.

Deloitte Touche Tohmatsu
ABN 74 490 121 060

Woodside Plaza
Level 14
240 St Georges Terrace
Perth WA 6000
GPO Box A46
Perth WA 6837 Australia

Tel: +61 8 9365 7000
Fax: +61 9365 7001
www.deloitte.com.au

20 February 2014

The Board of Directors
BioTech Capital Limited
1 Edmondson Crescent
KARRINYUP WA 6018

Dear Board Members

BioTech Capital Limited

In accordance with section 307C of the *Corporations Act 2001*, I am pleased to provide the following declaration of independence to the directors of BioTech Capital Limited.

As lead audit partner for the review of the half-year financial statements of BioTech Capital Limited for the period ended 31 December 2013, I declare that to the best of my knowledge and belief, there have been no contraventions of:

(i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and

(ii) any applicable code of professional conduct in relation to the review.

Yours sincerely

Deloitte Touche Tohmatsu

DELOITTE TOUCHE TOHMATSU

Neil Smith
Partner
Chartered Accountants

BIOTECH CAPITAL LIMITED ABN 45 091 979 172

CONDENSED
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE HALF YEAR ENDED 31 DECEMBER 2013

	31 December 2013 $	31 December 2012 $
Revenue from continuing operations (Note 2)	**8,722**	**28,812**
Other gains and losses (Note 2)	-	99,889
Expenses from continuing operations		
Director fees	(30,000)	(25,000)
Other expenses	(61,692)	(161,784)
Impairment loss on unlisted Investments	(1,737,966)	(379,053)
Total expenses from continuing operations	**(1,829,658)**	**(565,837)**
Loss from continuing operations before income tax expense	**(1,820,936)**	**(437,136)**
Income tax benefit (expense) relating to continuing operations	-	-
Net Loss for the period from continuing operations after income tax	**(1,820,936)**	**(437,136)**
Other comprehensive income		
Items that may be reclassified subsequently to profit or loss		
Net fair value losses on available for sale financial assets (net of tax)	-	(188,890)
Other comprehensive income for the period, net of tax	-	(188,890)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	**(1,820,936)**	**(626,026)**
Basic earnings per share (cents per share)	**(2.44)**	**(0.59)**
Diluted earnings per share (cents per share)	**(2.44)**	**(0.59)**

The accompanying notes form part of this financial report.

BIOTECH CAPITAL LIMITED ABN 45 091 979 172

CONDENSED STATEMENT OF FINANCIAL POSITION AS AT 31 DECEMBER 2013

	31 December 2013	30 June 2013
	$	$
CURRENT ASSETS		
Cash and cash equivalents	339,913	429,957
Trade and other receivables	5,397	585
Financial assets (Note 3)	-	2,737,966
TOTAL CURRENT ASSETS	345,310	3,168,508
NON CURRENT ASSETS		
Financial assets (Note 3)	1,000,000	-
TOTAL NON CURRENT ASSETS	1,000,000	-
TOTAL ASSETS	1,345,310	3,168,508
CURRENT LIABILITIES		
Trade and other payables	11,382	13,644
TOTAL CURRENT LIABILITIES	11,382	13,644
TOTAL LIABILITIES	11,382	13,644
NET ASSETS	**1,333,928**	**3,154,864**
EQUITY		
Issued Capital	39,338,817	39,338,817
Accumulated Losses	(38,004,889)	(36,183,953)
TOTAL EQUITY	**1,333,928**	**3,154,864**

The accompanying notes form part of this financial report

BIOTECH CAPITAL LIMITED ABN 45 091 979 172

CONDENSED STATEMENT OF CASH FLOWS
FOR THE HALF YEAR ENDED 31 DECEMBER 2013

	31 December 2013 $	31 December 2012 $
CASH FLOWS FROM OPERATING ACTIVITIES		
Interest received	8,722	28,812
Management agreement payments	-	(178,184)
Payments to suppliers and employees	(98,766)	(193,139)
Net cash (used in) operating activities	**(90,044)**	**(342,511)**
CASH FLOWS FROM INVESTING ACTIVITIES		
Proceeds from sale of investments	-	721,402
Net cash from investing activities	**-**	**721,402**
CASH FLOW FROM FINANCING ACTIVITIES		
Dividend paid	-	(745,540)
Net cash (used in) financing activities	**-**	**(745,540)**
Net (decrease) in cash held	**(90,044)**	**(366,649)**
Cash at 1 July 2013	**429,957**	**877,026**
Cash at 31 December 2013	**339,913**	**510,377**

The accompanying notes form part of this financial report

BIOTECH CAPITAL LIMITED ABN 45 091 979 172

CONDENSED STATEMENT OF CHANGES IN EQUITY
FOR THE HALF YEAR ENDED 31 DECEMBER 2013

	Issued Capital	Retained Earnings (Accumulated Losses)	Other Reserves	Total
	$	$	$	$
At 1 July 2012	**39,338,817**	**(34,936,664)**	**188,890**	**4,591,043**
Profit (loss) for the period	-	(437,136)	-	(437,136)
Other comprehensive income	-	-	(188,890)	(188,890)
Total comprehensive income for the period	-	(437,136)	(188,890)	(626,026)
Dividend paid	-	(745,540)	-	(745,540)
At 31 December 2012	**39,338,817**	**(36,119,340)**	**-**	**3,219,477**
At 1 July 2013	**39,338,817**	**(36,183,953)**	**-**	**3,154,864**
Profit (loss) for the period	-	(1,820,936)	-	(1,820,936)
Other comprehensive income	-	-	-	-
Total comprehensive income for the period	-	(1,820,936)	-	(1,820,936)
At 31 December 2013	**39,338,817**	**(38,004,889)**	**-**	**1,333,928**

The accompanying notes form part of this financial report

NOTES TO THE CONDENSED FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED 31 DECEMBER 2013

Note 1: Significant Accounting Policies

Basis of Preparation

The financial report of BioTech Capital Limited for the half-year ended 31 December 2013 was authorised for issue in accordance with a resolution of the directors on 20 February 2014. BioTech Capital Limited is a company incorporated in Australia and limited by shares which are publicly traded on the Australian Securities Exchange.

The half-year financial report does not include all notes of the type normally included within the annual financial report and therefore cannot be expected to provide as full an understanding of the financial performance, financial position and financing and investing activities of the entity as the full financial report.

The half-year financial report is a general purpose financial report prepared in accordance with the requirements of the *Corporations Act 2001* and Accounting Standards AASB 134: Interim Financial Reporting. Compliance with AASB 134 ensures compliance with International Financial Reporting Standards IAS 34 Interim Financial Reporting.

It is recommended that this financial report be read in conjunction with the annual financial report for the year ended 30 June 2013 and any publications made by BioTech Capital Limited during the half-year in accordance with continuous disclosure requirements arising under the *Corporations Act 2001*.

The accounting policies have been consistently applied and are consistent with those applied in the 30 June 2013 annual report, except for the adoption of amending standards mandatory for annual periods beginning on or after 1 July 2013, as noted below.

The half-year financial report has been prepared on a historical cost basis, except for financial assets that have been measured at fair value.

For the purpose of preparing the half-year financial report, the half-year has been treated as a discrete reporting period.

New or Revised Standards and Interpretations that are effective in the current reporting period

In the half-year ended 31 December 2013, the Company has reviewed all of the new and revised standards and interpretations issued by the AASB that are relevant to its operations and effective for annual reporting periods beginning on or after 1 July 2013. The company has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board that are relevant to their operations and are effective for the current financial reporting period. It has been determined by the Company that there is no impact, material or otherwise, of the new and revised standards and interpretations on its business and, therefore no change is necessary to the Company's accounting policies.

New and revised Standards and amendments thereof and Interpretations effective for the current half-year that are relevant to the Company include:

AASB 13 "Fair Value Measurement" and AASB 2011-8 "Amendments to Australian Accounting Standards arising from AASB 13".

Impact of the application of AASB13

The Company has applied AASB 13 for the first time in the current year. AASB 13 establishes a single source of guidance for fair value measurements and disclosures about fair value measurements. The scope of AASB 13 is broad; the fair value measurement requirements of AASB 13 apply to both financial instrument items and non-financial instrument items for which other AASBs require or permit fair value measurements and disclosures about fair value measurements, except for share-based payment transactions that are within the scope of AASB 2 'Share-based Payment', leasing transactions that are within the scope of AASB 117 'Leases', and measurements that have some similarities to fair value but are not fair value (e.g. net realisable value for the purposes of measuring inventories or value in use for impairment assessment purposes).

AASB 13 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction in the principal (or most advantageous) market at the measurement date under current market conditions. Fair value under AASB 13 is an exit price regardless of whether that price is directly observable or estimated using another valuation technique. Also, AASB 13 includes extensive disclosure requirements.

AASB 13 requires prospective application from 1 January 2013. In addition, specific transitional provisions were given to entities such that they need not apply the disclosure requirements set out in the Standard in comparative information provided for periods before the initial application of the Standard. In accordance with these transitional provisions, the Company has not made any new disclosures required by AASB 13 for the 2012 comparative period, the application of AASB 13 has not had any material impact on the amounts recognised in the financial statements.

Accounting Standards and Interpretations issued but not yet effective

Australian Accounting Standards and Interpretations that have recently been issued or amended but are not yet effective, have not been adopted by the consolidated entity for the half year ending 31 December 2013. Management are in the process of assessing the impact of the adoption of these standards and interpretations on the entity.

BIOTECH CAPITAL LIMITED ABN 45 091 979 172

NOTES TO THE CONDENSED FINANCIAL STATEMENTS FOR THE HALF YEAR ENDED 31 DECEMBER 2013

Note 2: Revenue from continuing operations

	31 December 2013 $	31 December 2012 $
Revenue from continuing operations		
Finance Revenue	8,722	28,812
Total revenue from continuing operations	**8,722**	**28,812**
Other gains and losses		
Net gain on remeasurement of liability	-	99,889
Total other gains and losses	**-**	**99,889**

Note 3: Financial Assets

	31 December 2013 $	30 June 2013 $
Current		
Available for Sale Financial Assets:		
Investment in Sensear Pty Ltd – at directors' valuation	-	2,737,966
Total Available for sale Financial Assets	-	2,737,966
Non-Current		
Available for Sale Financial Assets:		
Investment in Sensear Pty Ltd – at directors' valuation	1,000,000	-
Total Available for sale Financial Assets	1,000,000	-
Movement		
Opening balance	2,737,966	4,051,046
Impairment loss on unlisted investments	(1,737,966)	(379,053)
Disposals	-	(711,804)
Revaluations	-	(222,223)
Closing balance	1,000,000	2,737,966

Note 3: Financial Assets (continued)

On 12 August 2010, the Company announced it was adopting a change in investment strategy and restructuring. It is currently the Board's intention to liquidate the current portfolio in an orderly manner with proceeds being returned to shareholders through dividends. Only one investment remains being Sensear Pty Ltd. The Board acknowledges, due to the nature and liquidity of unlisted investments, that realisation of this investment may take longer than 12 months.

Unlisted shares

The fair value of unlisted available for sale investments are determined by directors valuations, which is based on their experience in the industry and the average realisable value in the short term based on their change in investment strategy. The directors have used assumptions, such as impacts on estimated cash flows, project updates and other market data available in determining their valuation of unlisted investments.

Impairment Loss on Unlisted Investments

An allowance for impairment loss is recognised when there is objective evidence that unlisted investments are impaired. Based on the best estimate of information available, the Board decided to record an impairment loss of $1,737,966 (31 December 2012: $379,053) for the period.

Other Comprehensive Income

Included in movements in other comprehensive income are net fair value losses on available for sale financial assets of $Nil (31 December 2012 $222,223) relating to unlisted investments.

Note 4: Contingent Liabilities

There has been no material change in contingent liabilities since the last annual reporting date.

Note 5: Subsequent Events

No matters have arisen between the end of the half-year ended 31 December 2013 and the date of this report, in the opinion of the directors of the company, that will affect significantly the operations of the entity, the results of those operations, or the state of the affairs of the entity, in subsequent financial years.

Note 6: Operating Segments Information

Operating segments have been identified on the basis of internal reports of the company that are regularly reviewed by the chief operating decision maker in order to allocate resources to the segments and to assess their performance. The chief operating decision maker has been identified as the Board of Directors. On a regular basis, the board receives financial information on a company basis similar to the financial statements presented in the financial report, to manage and allocate their resources.

Note 7: Financial Instruments

7.1 Fair value of the Company's financial assets and financial liabilities that are measured at fair value on a recurring basis

Some of the Company's financial assets and financial liabilities are measured at fair value at the end of each reporting period. The following table gives information about how the fair values of these financial assets and financial liabilities are determined (in particular, the valuation techniques and inputs used).

Financial assets/ financial liabilities	**Fair value as at**	**Fair value as at**	**Fair value hierarchy**	**Valuation techniques and key inputs**	**Significant unobservable inputs**	**Relationship of unobservable inputs to fair value**
	31/12/2013	**31/12/2012**				
Available for sale financial assets	Unlisted equity securities in Sensear Pty Ltd $1,000,000	Unlisted equity securities in Sensear Pty Ltd $2,737,966	Level 3	Board valuation as described in Note 3.	Discount for lack of marketability.	The higher the discount, the lower the fair value.

If the above unobservable inputs to the valuation model were 10% higher/lower while all the other variables were held constant, the carrying amount of the financial asset would decrease / increase by $100,000 (31 December 2012: decrease / increase by $273,797).

There were no transfers between levels in the period.

7.2 Reconciliation of Level 3 fair value measurements

31 December 2013	**Available for sale unlisted shares**
	$
Opening balance	2,737,966
Total gains or losses:	
- in profit or loss	(1,737,966)
- in other comprehensive income	-
Closing balance	1,000,000

31 December 2012	**Available for sale unlisted shares**
	$
Opening balance	3,339,242
Total gains or losses:	
- in profit or loss	(379,053)
- in other comprehensive income	(222,223)
Closing balance	2,737,966

BIOTECH CAPITAL LIMITED ABN 45 091 979 172

DIRECTORS' DECLARATION

In the opinion of the directors:

1. The financial statements and notes of the entity, are in accordance with the Corporations Act 2001:

   a) Comply with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001; and

   b) give a true and fair view of the company's financial position as at 31 December 2013 and of its performance for the half-year ended on that date.

2. There are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.

E Taylor
Director

Dated this 20th day of February 2014

Deloitte.

Deloitte Touche Tohmatsu
ABN 74 490 121 060

Woodside Plaza
Level 14
240 St Georges Terrace
Perth WA 6000
GPO Box A46
Perth WA 6837 Australia

Tel: +61 8 9365 7000
Fax: +61 9365 7001
www.deloitte.com.au

Independent Auditor's Review Report to the Members of BioTech Capital Limited

We have reviewed the accompanying half-year financial report of BioTech Capital Limited, which comprises the condensed statement of financial position as at 31 December 2013, and the condensed statement of profit or loss and other comprehensive income, the condensed statement of cash flows and the condensed statement of changes in equity for the half-year ended on that date, selected explanatory notes and, the directors' declaration as set out on pages 6 to 16.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the company's financial position as at 31 December 2013 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of BioTech Capital Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Auditor's Independence Declaration

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of BioTech Capital Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.

Deloitte

Basis for Qualified Conclusion

As disclosed in Note 3 to the half-year financial report, the company has within available for sale financial assets, an investment in an unlisted company at directors' valuation of $1,000,000 as at 31 December 2013 (30 June 2013: $2,737,966) ("the asset"). Further, included in the statement of profit or loss and other comprehensive income are impairment losses of $1,737,966 (31 December 2012: $379,053) and in other comprehensive income are net fair value losses of Nil (31 December 2012: losses of $188,890) relating to the asset. As set out in Note 3, the directors have valued the asset based on their experience in the industry and the average realisable value in the short term based on their change in investment strategy. Australian Accounting Standard AASB 139 "*Financial Instruments: Recognition and Measurement*" requires financial assets classified as available for sale financial assets to be recognised and measured at their fair values, with subsequent changes in fair values to be recognised in other comprehensive income, except for impairment losses. We have been unable to obtain sufficient appropriate evidence of the fair value of the asset and, accordingly, we have been unable to determine whether the fair values at those dates and changes in fair values and impairment losses have been appropriately recognised.

Qualified Conclusion

Based on our review, which is not an audit, except for the possible effects of the matter described in the Basis for Qualified Conclusion paragraph, we have not become aware of any matter that makes us believe that the half-year financial report of BioTech Capital Limited is not in accordance with the *Corporations Act 2001*, including:

(a) giving a true and fair view of the company's financial position as at 31 December 2013 and of its performance for the half-year ended on that date; and

(b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Deloitte Touche Tohmatsu

DELOITTE TOUCHE TOHMATSU

Neil Smith

Neil Smith
Partner
Chartered Accountants
Perth, 20 February 2014